EORTC’s Participation at the ESTRO Congress 2024

We are delighted to announce EORTC’s participation at the ESTRO Congress 2024 taking place from 3 to 7 May 2024 in Glasgow, UK. This year’s theme is Radiation Oncology: Bridging the Care Gap.

Save the date for the ESTRO-EORTC joint session on innovations in re-irradiation clinical trial design on Saturday 4 May 2024, from 08:45 to 10:00 AM.

In addition to the joint session, we are proud to showcase five abstracts on the topic of radiation oncology: three oral presentations and two digital posters. For a detailed overview, please consult the table below.

ESTRO-EORTC Joint Session

Session Scheduled on
ESTRO-EORTC – Innovations in re-irradiation clinical trial design
Session Type: Interdisciplinary
Session code: 1080
Saturday 04 May
08:45 – 10:00 GMT+1
Hall 2

EORTC Abstracts

Abstract Scheduled on
Pattern-of-Care Analysis for Radiotherapy of Cutaneous Lymphomas among
the European Organisation for Research and Treatment of Cancer (EORTC)
Khaled Elsayad, Germany
Session Type: Proffered Papers
Saturday 04 May
10:30 – 11:30 GMT+1
Interim results of the prospective RTQA procedures for HALT
(CRUK/16/020, EORTC 1702-LCG-ROG)
Daniel Portik, EORTC HQ
Session Type: Proffered Papers
Saturday 04 May
17:00 – 18:00 GMT+1
Hall 3
Early Quality-of-Life after metastases-directed SBRT – results of the 
ESTRO & EORTC OligoCare cohort*
Daniela Greto, Italy
Session Type: Proffered paper
Saturday 04 May
17:00 – 18:00 GMT+1
Hall 2
Head-to-head comparison for breast RT planning: knowledge-based
planning vs. deep learning solution
Daniel Portik, EORTC HQ
Digital Poster
A Trials within Cohorts comparing 1 fraction vs multiple-fraction
SBRT in oligometastatic cancer*
Piet Ost, Belgium
Digital Poster

*The Oligocare project is part of the E²-RADIatE platform. The E²-RADIatE platform and Oligocare project are supported by Walgreens Boots Alliance. OligoCare is also supported by Stiftung Bruckner.

Back to news list

Related News

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma